ATE530180T1 - Verfahren zur ermittlung der individualen risikoprofile atherosklerotischen erkrankungen - Google Patents

Verfahren zur ermittlung der individualen risikoprofile atherosklerotischen erkrankungen

Info

Publication number
ATE530180T1
ATE530180T1 AT04010424T AT04010424T ATE530180T1 AT E530180 T1 ATE530180 T1 AT E530180T1 AT 04010424 T AT04010424 T AT 04010424T AT 04010424 T AT04010424 T AT 04010424T AT E530180 T1 ATE530180 T1 AT E530180T1
Authority
AT
Austria
Prior art keywords
determining
individual
individual risk
risk profiles
atherosclerotic diseases
Prior art date
Application number
AT04010424T
Other languages
English (en)
Inventor
Paul Ridker
Charles H Hennekens
Original Assignee
Brigham & Womens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27366025&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE530180(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Brigham & Womens Hospital filed Critical Brigham & Womens Hospital
Application granted granted Critical
Publication of ATE530180T1 publication Critical patent/ATE530180T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/323—Arteriosclerosis, Stenosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Analytical Chemistry (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
AT04010424T 1997-04-02 1998-04-02 Verfahren zur ermittlung der individualen risikoprofile atherosklerotischen erkrankungen ATE530180T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4303997P 1997-04-02 1997-04-02
US4195097P 1997-04-02 1997-04-02
US7089498P 1998-01-09 1998-01-09

Publications (1)

Publication Number Publication Date
ATE530180T1 true ATE530180T1 (de) 2011-11-15

Family

ID=27366025

Family Applications (2)

Application Number Title Priority Date Filing Date
AT04010424T ATE530180T1 (de) 1997-04-02 1998-04-02 Verfahren zur ermittlung der individualen risikoprofile atherosklerotischen erkrankungen
AT98917992T ATE290375T1 (de) 1997-04-02 1998-04-02 Verwendung eines mittels zur verminderung des risikos kardiovaskulärer erkrankungen

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT98917992T ATE290375T1 (de) 1997-04-02 1998-04-02 Verwendung eines mittels zur verminderung des risikos kardiovaskulärer erkrankungen

Country Status (12)

Country Link
US (1) US6040147A (de)
EP (4) EP1493439B1 (de)
JP (3) JP2008120800A (de)
AT (2) ATE530180T1 (de)
AU (1) AU7100898A (de)
CA (1) CA2285091A1 (de)
CY (1) CY1112261T1 (de)
DE (1) DE69829293T2 (de)
DK (2) DK1493439T3 (de)
ES (2) ES2239801T3 (de)
PT (2) PT1493439E (de)
WO (1) WO1998043630A1 (de)

Families Citing this family (140)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7097839B1 (en) 1993-10-26 2006-08-29 Thomas Jefferson University ST receptor binding compounds and methods of using the same
US6429017B1 (en) * 1999-02-04 2002-08-06 Biomerieux Method for predicting the presence of haemostatic dysfunction in a patient sample
US6321164B1 (en) 1995-06-07 2001-11-20 Akzo Nobel N.V. Method and apparatus for predicting the presence of an abnormal level of one or more proteins in the clotting cascade
US6898532B1 (en) 1995-06-07 2005-05-24 Biomerieux, Inc. Method and apparatus for predicting the presence of haemostatic dysfunction in a patient sample
US7030152B1 (en) 1997-04-02 2006-04-18 The Brigham And Women's Hospital, Inc. Systematic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease
US6727102B1 (en) * 1997-06-20 2004-04-27 Leuven Research & Development Vzw Assays, antibodies, and standards for detection of oxidized and MDA-modified low density lipoproteins
US6502040B2 (en) 1997-12-31 2002-12-31 Biomerieux, Inc. Method for presenting thrombosis and hemostasis assay data
ES2212615T3 (es) * 1998-08-27 2004-07-16 Mayo Foundation For Medical Education And Research Metodos y materiales para el diagnostico de una angina inestable.
US6309888B1 (en) * 1998-09-04 2001-10-30 Leuven Research & Development Vzw Detection and determination of the stages of coronary artery disease
JP4486260B2 (ja) * 1999-02-04 2010-06-23 バイオメリュー・インコーポレイテッド 患者サンプルにおける止血機能不全の存在を予測するための方法および装置
AU782386C (en) * 1999-08-31 2006-08-10 Brigham And Women's Hospital Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases
EP1767222A1 (de) * 1999-08-31 2007-03-28 The Brigham And Women's Hospital, Inc. Systemische Entzündungsmarker als diagnostisches Werkzeug um arteriosklerotische Erkrankungen zu verhindern
EP1520590A1 (de) * 1999-08-31 2005-04-06 The Brigham and Women's Hospital, Inc. Systemische Entzündungsmarker als diagnostisches Werkzeug um arteriosklerotische Erkrankungen zu verhindern
GB9929140D0 (en) * 1999-12-10 2000-02-02 Univ Geneve Diagnostic assay for stroke
US7179612B2 (en) * 2000-06-09 2007-02-20 Biomerieux, Inc. Method for detecting a lipoprotein-acute phase protein complex and predicting an increased risk of system failure or mortality
GB0019172D0 (en) 2000-08-05 2000-09-27 Glaxo Group Ltd Novel compounds
US6787532B2 (en) 2000-08-05 2004-09-07 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivatives
US6858596B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
US6750210B2 (en) 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
US6777399B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6858593B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
WO2002012266A1 (en) 2000-08-05 2002-02-14 Glaxo Group Limited 17.beta.-carbothioate 17.alpha.-arylcarbonyloxyloxy androstane derivative as anti-inflammatory agents
US6777400B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6759398B2 (en) 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
US7199102B2 (en) 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
US7144862B2 (en) * 2000-08-24 2006-12-05 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
WO2002038794A2 (en) * 2000-11-09 2002-05-16 The Brigham And Women's Hospital, Inc. Cardiovascular disease diagnostic and therapeutic targets
WO2002048715A2 (en) * 2000-12-14 2002-06-20 The Brigham And Women's Hospital, Inc. Inflammatory markers for detection and prevention of diabetes mellitus
US6855509B2 (en) 2000-12-19 2005-02-15 Instrumentation Laboratory Company Protein S functional assay and kit therefor
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
AU2002249893B2 (en) 2001-01-02 2007-05-24 The Cleveland Clinic Foundation Myeloperoxidase, a risk indicator for cardiovascular disease
US6500630B2 (en) 2001-01-12 2002-12-31 Mayo Foundation For Medical Education And Research Marker for inflammatory conditions
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
IL156445A0 (en) * 2001-01-26 2004-01-04 Schering Corp Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
US20060287254A1 (en) * 2001-01-26 2006-12-21 Schering Corporation Use of substituted azetidinone compounds for the treatment of sitosterolemia
AR035533A1 (es) 2001-01-26 2004-06-02 Schering Corp Uso de por lo menos un inhibidor de la absorcion de los esteroles o sus sales, solvatos, prodrogas farmaceuticamente aceptables o mezclas de los mismos para la preparacion de un medicamento para el tratamiento de la sitosterolemia, composiciones farmaceuticas, el uso de dichas composiciones para la
EP1401456A4 (de) * 2001-02-21 2005-04-20 Merck & Co Inc Verfahren zur bestimmung des wirkungsgrades von verbesserungsmitteln des cholesterinrückwärtstransports
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
US20040253637A1 (en) * 2001-04-13 2004-12-16 Biosite Incorporated Markers for differential diagnosis and methods of use thereof
US7713705B2 (en) 2002-12-24 2010-05-11 Biosite, Inc. Markers for differential diagnosis and methods of use thereof
PT1383786E (pt) 2001-04-30 2008-12-30 Glaxo Group Ltd Derivados anti-inflamatórios de éster 17.beta-carbotioato de androstano com um grupo éster ciclíco na posição 17.alfa
US7608406B2 (en) 2001-08-20 2009-10-27 Biosite, Inc. Diagnostic markers of stroke and cerebral injury and methods of use thereof
US7053080B2 (en) * 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
MXPA04002573A (es) 2001-09-21 2004-06-18 Schering Corp Tratamiento de xantoma con derivados de azetidinona como inhibidores de la absorcion de esterol.
JP2005515407A (ja) 2001-11-05 2005-05-26 ザ ブライアム アンド ウィミンズ ホスピタル インコーポレーテッド アテローム硬化症の予後マーカーとしての可溶性ｃｄ４０ｌ（ｃｄ１５４）
US7527932B2 (en) * 2001-11-09 2009-05-05 Medstar Research Institute, Inc. Method of using physiological markers to estimate cardiovascular risk
AU2002352726A1 (en) 2001-11-15 2003-06-10 Galileo Laboratories, Inc. Formulations and methods for treatment or amelioration of inflammatory conditions
US20040071633A1 (en) * 2002-02-19 2004-04-15 Wright Samuel D. Method for determining efficacy of reverse cholesterol transport enhancing agents
DK3072978T3 (en) 2002-05-09 2018-09-17 Brigham & Womens Hospital Inc : 1L1RL-1 AS A CARDIOVASCULAR DISEASE MARKER
US7345091B2 (en) * 2002-07-29 2008-03-18 Cardax Pharmaceuticals, Inc. Carotenoid ether analogs or derivatives for the inhibition and amelioration of disease
EP2392562B1 (de) 2002-07-29 2018-03-07 Cardax Pharma, Inc. Strukturelle Carotenoidanaloge zur Hemmung und Abschwächung einer Erkrankung
US20050009788A1 (en) * 2002-07-29 2005-01-13 Lockwood Samuel Fournier Carotenoid ester analogs or derivatives for controlling connexin 43 expression
US20050004235A1 (en) * 2002-07-29 2005-01-06 Lockwood Samuel Fournier Carotenoid analogs or derivatives for the inhibition and amelioration of liver disease
US7763649B2 (en) * 2002-07-29 2010-07-27 Cardax Pharmaceuticals, Inc. Carotenoid analogs or derivatives for controlling connexin 43 expression
US7320997B2 (en) * 2002-07-29 2008-01-22 Cardax Pharmaceuticals, Inc. Pharmaceutical compositions including carotenoid ester analogs or derivatives for the inhibition and amelioration of disease
US20050049248A1 (en) * 2002-07-29 2005-03-03 Lockwood Samuel Fournier Carotenoid ether analogs or derivatives for controlling C-reactive protein levels
US20050059635A1 (en) * 2002-07-29 2005-03-17 Lockwood Samuel Fournier Carotenoid ester analogs or derivatives for controlling C-reactive protein levels
US20050026874A1 (en) * 2002-07-29 2005-02-03 Lockwood Samuel Fournier Carotenoid ether analogs or derivatives for the inhibition and amelioration of liver disease
US7375133B2 (en) * 2002-07-29 2008-05-20 Cardax Pharmaceuticals, Inc. Pharmaceutical compositions including carotenoid ether analogs or derivatives for the inhibition and amelioration of disease
US20050148517A1 (en) * 2002-07-29 2005-07-07 Lockwood Samuel F. Carotenoid ether analogs or derivatives for controlling connexin 43 expression
US7723327B2 (en) * 2002-07-29 2010-05-25 Cardax Pharmaceuticals, Inc. Carotenoid ester analogs or derivatives for the inhibition and amelioration of liver disease
US7521584B2 (en) * 2002-07-29 2009-04-21 Cardax Pharmaceuticals, Inc. Carotenoid analogs or derivatives for the inhibition and amelioration of disease
US20050143475A1 (en) * 2002-07-29 2005-06-30 Lockwood Samuel F. Carotenoid analogs or derivatives for the inhibition and amelioration of ischemic reperfusion injury
US20050059659A1 (en) * 2002-07-29 2005-03-17 Lockwood Samuel Fournier Carotenoid analogs or derivatives for controlling C-reactive protein levels
WO2004028470A2 (en) 2002-09-27 2004-04-08 Martek Biosciences Corporation Prophylactic docosahexaenoic acid therapy for patients with subclinical inflammation
US7507531B2 (en) * 2002-10-17 2009-03-24 Decode Genetics Chf. Use of 5-lipoxygenase activating protein (FLAP) gene to assess susceptibility for myocardial infarction
US7851486B2 (en) * 2002-10-17 2010-12-14 Decode Genetics Ehf. Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment
US20080293750A1 (en) * 2002-10-17 2008-11-27 Anna Helgadottir Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment
US20060019269A1 (en) * 2002-10-17 2006-01-26 Decode Genetics, Inc. Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment
WO2004043457A1 (en) 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
US20040097433A1 (en) * 2002-11-15 2004-05-20 Sekhar Boddupalli Chroman derivatives for the reduction of inflammation symptoms
EP1575567A4 (de) * 2002-12-12 2008-10-08 Activbiotics Inc Verfahren und reagentien zur behandlungoder vorbeugung von arteriosklerose und damit einhergehenden krankheiten
US20050026168A1 (en) * 2002-12-13 2005-02-03 Genesis Group Inc. Method for the detection of risk factors associated with myocardial infarction
GB0229747D0 (en) * 2002-12-20 2003-01-29 Axis Shield Asa Assay
EP1601668B1 (de) * 2003-03-07 2008-08-27 Schering Corporation Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
US7459442B2 (en) * 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
JP2006519869A (ja) 2003-03-07 2006-08-31 シェーリング　コーポレイション 置換アゼチジノン化合物、置換アゼチジノン化合物を調製するためのプロセス、それらの処方物および使用
CA2517572C (en) 2003-03-07 2011-12-13 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
WO2004080414A2 (en) * 2003-03-12 2004-09-23 Mullally John P Composition and method for treating inflammations by reducing c-reactive protein
US20040192660A1 (en) * 2003-03-12 2004-09-30 Mullally John P. Protocol for improving vision
US20050026979A1 (en) * 2003-07-31 2005-02-03 Maha Ghazzi Methods for treating inflammation and inflammation-associated diseases with a statin and ether
US20050272051A1 (en) * 2003-09-17 2005-12-08 Decode Genetics Ehf. Methods of preventing or treating recurrence of myocardial infarction
JP2007518062A (ja) * 2003-09-29 2007-07-05 バイオサイト インコーポレイテッド 敗血症を診断する方法および診断するための組成物
US20080085329A1 (en) * 2003-10-22 2008-04-10 Fred Hutchinson Cancer Research Center, Inc. Methods, Compositions and Devices for Inducing Stasis in Cells, Tissues, Organs, and Organisms
WO2005046675A2 (en) * 2003-11-07 2005-05-26 Jordan Holtzman Methods for enhancing glutathione peroxidase activity
US9408891B2 (en) * 2003-11-12 2016-08-09 The Trustees Of The University Of Pennsylvania Methods of using gelsolin to treat or prevent bacterial sepsis
WO2005046454A2 (en) * 2003-11-12 2005-05-26 Trustrees Of The University Of Pennsylvania Methods of using gelsolin to treat or prevent bacterial sepsis
EP2306192B1 (de) 2003-12-05 2015-10-14 The Cleveland Clinic Foundation Risikomarker für eine Herzkreislaufkrankheit
EP1696859A4 (de) * 2003-12-09 2007-08-22 Essential Skincare Llc Verfahren zur verbesserung der insulinsensitivität durch verabreichung eines antitrypsin-hemmers
US20100216863A1 (en) * 2004-01-30 2010-08-26 Decode Genetics Ehf. Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment
US8158362B2 (en) * 2005-03-30 2012-04-17 Decode Genetics Ehf. Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype
US20050181451A1 (en) * 2004-02-12 2005-08-18 Bates Harold M. Detection of asymptomatic coronary artery disease using atherogenic proteins and acute phase reactants
WO2005083430A1 (en) * 2004-02-25 2005-09-09 Massachusetts Eye & Ear Infirmary Biomarkers for age-related macular degeneration (amd)
US20060058269A1 (en) * 2004-04-14 2006-03-16 Lockwood Samuel F Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation
EP1750723A1 (de) * 2004-04-14 2007-02-14 Hawaii Biotech, Inc. Carotenoid-analoga oder derivate zur hemmung und linderung von entzündungen
KR101300929B1 (ko) * 2004-05-12 2013-08-27 더 브리검 앤드 우먼즈 하스피털, 인크. 감염 치료를 위한 겔솔린의 용도
WO2005110422A2 (en) * 2004-05-19 2005-11-24 Boehringer Ingelheim International Gmbh Treatment of diseases associated with altered level of amyloid beta peptides
ES2571929T3 (es) * 2004-05-26 2016-05-27 Region Nordjylland Procedimiento para determinar la cantidad de CD36 circulante
US8335652B2 (en) 2004-06-23 2012-12-18 Yougene Corp. Self-improving identification method
US8027791B2 (en) 2004-06-23 2011-09-27 Medtronic, Inc. Self-improving classification system
US20060020043A1 (en) * 2004-07-26 2006-01-26 Roger Berlin Methods and compositions for reducing C-reactive protein
US7378396B2 (en) * 2004-08-11 2008-05-27 The Cleveland Clinic Foundation Therapeutic agents and methods for cardiovascular disease
WO2006031592A1 (en) * 2004-09-09 2006-03-23 University Of Massachusetts Disease markers for early stage atherosclerosis
US20060088860A1 (en) * 2004-09-13 2006-04-27 Lipomics Technologies, Inc. Metabolite markers for weight management
US9164104B2 (en) 2004-10-06 2015-10-20 The Brigham And Women's Hospital, Inc. Relevance of achieved levels of markers of systemic inflammation following treatment
WO2006063132A2 (en) * 2004-12-06 2006-06-15 The Regents Of The University Of California Methods for improving the structure and function of arterioles
PT1879599E (pt) * 2005-04-20 2014-01-23 Hutchinson Fred Cancer Res Métodos, composições e artigos de fabrico para aumentar a capacidade de sobrevivência de células, tecidos, órgãos, e organismos
US20080293639A1 (en) * 2005-04-29 2008-11-27 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
KR20080007491A (ko) * 2005-04-29 2008-01-21 더 리전트 오브 더 유니버시티 오브 캘리포니아 염증성 반응을 특징으로 하는 병리를 치료하기 위한 펩티드및 펩티드 모방체
US20070099239A1 (en) * 2005-06-24 2007-05-03 Raymond Tabibiazar Methods and compositions for diagnosis and monitoring of atherosclerotic cardiovascular disease
AU2007216009A1 (en) * 2006-02-14 2007-08-23 Pola Chemical Industries Inc. Skin-whitening cosmetic
KR101556790B1 (ko) 2006-03-15 2015-10-01 더 브리검 앤드 우먼즈 하스피털, 인크. 염증성 질환의 진단 및 치료를 위한 겔솔린의 용도
ES2651619T3 (es) * 2006-03-15 2018-01-29 The Brigham And Women's Hospital, Inc. Uso de gelsolina para tratar esclerosis múltiple y diagnosticar enfermedades neurológicas
AU2007244927B2 (en) * 2006-04-24 2012-01-12 Critical Care Diagnostics, Inc. Predicting mortality and detecting severe disease
ATE517341T1 (de) * 2006-04-27 2011-08-15 Critical Care Diagnostics Inc Interleukin-33 (il-33) zur diagnose und vorhersage von herz-gefäss-erkrankungen
EP2021796B1 (de) * 2006-05-01 2012-02-08 Critical Care Diagnostics, Inc. Diagnose von herz-kreislauf-erkrankung
PL2019965T3 (pl) * 2006-05-02 2015-10-30 Critical Care Diagnostics Inc Rozpoznawanie różnicowe chorób układu oddechowego i sercowo-naczyniowego
EP2302395B1 (de) 2006-06-07 2015-04-15 Health Diagnostic Laboratory, Inc. Mit arteriovaskulären Ereignissen assoziierte Marker und Verfahren zu ihrer Verwendung
AU2008213472A1 (en) * 2007-02-05 2008-08-14 Aarhus Universitet A method for diagnosing atherosclerotic plaques by measurement of CD36
US8557767B2 (en) 2007-08-28 2013-10-15 Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
AU2008296478B9 (en) 2007-08-28 2015-03-19 The Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
WO2009032722A1 (en) * 2007-08-29 2009-03-12 The Cleveland Clinic Foundation Carbamylated proteins and risk of cardiovascular disease
US9423405B2 (en) * 2007-12-05 2016-08-23 The Cleveland Clinic Foundation Trimethylamine compounds as risk predictors of cardiovascular disease
HUE032875T2 (en) * 2008-01-25 2017-11-28 Massachusetts Gen Hospital Diagnostic and therapeutic applications of gelsolin in renal failure
PL2269063T3 (pl) 2008-04-18 2014-04-30 Critical Care Diagnostics Inc Rokowanie ryzyka głównych niekorzystnych zdarzeń sercowych
EP2291182A1 (de) * 2008-05-13 2011-03-09 Genmedica Therapeutics SL Salicylat-konjugate zur behandlung von stoffwechselerkrankungen
WO2010014771A1 (en) * 2008-08-01 2010-02-04 Ore Pharmaceuticals Inc. Romazarit for treating metabolic diseases
US11835503B2 (en) 2009-05-28 2023-12-05 The Cleveland Clinic Foundation TMA-formation inhibitor treatment for elevated TMA-containing compound diseases
US10241093B2 (en) 2009-05-28 2019-03-26 The Cleveland Clinic Foundation Trimethylamine-containing compounds for diagnosis and prediction of disease
JP5379616B2 (ja) 2009-09-09 2013-12-25 株式会社日立製作所 粥状硬化性動脈硬化のマーカー因子と用途
KR20120101064A (ko) * 2009-11-13 2012-09-12 비쥐 메디신, 인코포레이티드 심근 경색의 위험 인자 및 예측
ES2750126T3 (es) 2011-03-17 2020-03-25 Critical Care Diagnostics Inc Procedimientos de predicción del riesgo de un resultado clínico adverso
US8708906B1 (en) * 2011-09-07 2014-04-29 Allen J. Orehek Method for the prevention of dementia and Alzheimer's disease
CN104737170A (zh) 2012-08-21 2015-06-24 重症监护诊断股份有限公司 多标记风险分层
SG11201504340YA (en) * 2012-12-12 2015-07-30 Mesoblast Inc Treatment of diseases of endothelial dysfunction and inflammation
CN106460062A (zh) 2014-05-05 2017-02-22 美敦力公司 用于scd、crt、crt‑d或sca治疗识别和/或选择的方法和组合物
MX383117B (es) 2014-07-31 2025-03-13 Anji Pharmaceuticals Inc Péptidos miméticos de la apoe y mayor potencia para depurar el colesterol en plasma.
EP3191091B1 (de) 2014-09-12 2020-08-26 Children's Medical Center Corporation Formulierungen einer diätetischen emulsion und verfahren zur verwendung davon
FI127416B (en) * 2016-09-29 2018-05-31 Oy Medix Biochemica Ab Cardiovascular risk assessment method

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US3832253A (en) 1973-03-21 1974-08-27 Baxter Laboratories Inc Method of making an inflatable balloon catheter
US4287202A (en) * 1978-05-26 1981-09-01 Horrobin David F Treatment and/or prophylaxis of spasms of coronary arteries
US4667014A (en) 1983-03-07 1987-05-19 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
CA1200416A (en) 1983-05-13 1986-02-11 Societe Des Produits Nestle S.A. Food process
JPS60139621A (ja) * 1983-12-27 1985-07-24 Grelan Pharmaceut Co Ltd 抗血栓剤
JPS625970A (ja) * 1985-03-15 1987-01-12 Terumo Corp ピラジン誘導体およびこれを含有する血小板凝集抑制剤
US4902630A (en) * 1985-07-22 1990-02-20 Abbott Laboratories Fluorescence polarization immunoassy and reagents for measurement of c-reactive protein
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5003065A (en) * 1988-06-14 1991-03-26 Carey Merritt Compounds and process for measuring c-reactive protein
US5500345A (en) * 1989-04-25 1996-03-19 Iatron Laboratories, Inc. Hybridomas producing monoclonal antibodies specific for C-reactive protein and methods for detection of C-reactive protein
US5272258A (en) * 1989-06-29 1993-12-21 Rush-Presbyterian-St. Luke's Medical Center Monoclonal antibodies to C-reactive protein
GB9019812D0 (en) 1990-09-11 1990-10-24 Scotgen Ltd Novel antibodies for treatment and prevention of infection in animals and man
JPH04167172A (ja) 1990-10-31 1992-06-15 Nec Corp ベクトルプロセッサ

Also Published As

Publication number Publication date
US6040147A (en) 2000-03-21
EP1003501B1 (de) 2005-03-09
EP1493439B1 (de) 2011-10-26
DK1003501T3 (da) 2005-07-18
JP3805381B2 (ja) 2006-08-02
JP2015079003A (ja) 2015-04-23
EP1003501B9 (de) 2005-06-08
EP1003501A4 (de) 2001-01-17
DE69829293D1 (de) 2005-04-14
JP2008120800A (ja) 2008-05-29
JP2013036996A (ja) 2013-02-21
EP1003501A1 (de) 2000-05-31
ES2239801T3 (es) 2005-10-01
PT1493439E (pt) 2012-01-10
EP1493439A1 (de) 2005-01-05
DK1493439T3 (da) 2012-01-30
ATE290375T1 (de) 2005-03-15
EP2305235A1 (de) 2011-04-06
DE69829293T2 (de) 2006-04-13
AU7100898A (en) 1998-10-22
PT1003501E (pt) 2005-07-29
CA2285091A1 (en) 1998-10-08
WO1998043630A1 (en) 1998-10-08
EP2305236A1 (de) 2011-04-06
JP2001525058A (ja) 2001-12-04
CY1112261T1 (el) 2015-12-09
ES2374621T3 (es) 2012-02-20

Similar Documents

Publication Publication Date Title
ATE530180T1 (de) Verfahren zur ermittlung der individualen risikoprofile atherosklerotischen erkrankungen
NO20020203D0 (no) Fremgangsmåte og apparat for bestemmelse av underjordiske reservoarers egenskaper
DE69738362D1 (de) Methode zur Nivellierungsüberwachung mit verbesserter Genauigkeit für eine Aufzugskabine
NO20015096L (no) Måling og bruk av molekul¶re interaksjoner
NO20010994D0 (no) FremgangsmÕte og innretning for bestemmelse av beskaffenheten av underjordiske reservoarer
DE60115314D1 (de) Verfahren für die Auswertung von Bildern zur Defekterkennung
FI946164A0 (fi) Menetelmä ja laite kunto- tai urheiluharjoittelun rasitustasojen ja harjoittelun rasittavuuden määrittämiseksi
SG137650A1 (en) Method for rewarding customer loyalty with respect to a lease agreement
DE69833835D1 (de) Verfahren zur Bestimmung der Dicke eines optischen Prüfkörpers
FI982172A7 (fi) Menetelmä hissin pitojarrun toiminnan ja/tai kunnon määrittämiseksi ja pitojarru
ATA93097A (de) Verfahren zur bestimmung eines alkaliions
DE59914773D1 (de) VERFAHREN ZUR BESTIMMUNG DER NOx-KONZENTRATION
DE59806044D1 (de) Verfahren zur ermittlung von segmentzeiten
DE59706134D1 (de) Verfahren zur ermittlung der funktionstauglichkeit von schmierölen
DE50204097D1 (de) Verfahren zur ermittlung von auswirkungen von konstruktionsentscheidungen
FI20030863L (fi) Menetelmä ja laitteisto tiemerkinnän kuntotason määrittämiseksi
DE59801703D1 (de) Verfahren zur ansteuerung eines aggregatelagers
DE69938780D1 (de) VERFAHREN ZUR UNTERSUCHUNG DER IgA-NEPHROPATHIE
FI940225A0 (fi) Menetelmä näytteessä olevan metallin määrittämiseksi
FI20021565A0 (fi) Menetelmä ja järjestelmä teräksen karkaisusyvyyden määrittämiseksi
ATE388632T1 (de) Verfahren zur überwachung von schweinen
FR2749308B1 (fr) Sondes nucleotidiques et procede pour determiner le typage hla dqb1
ATE320602T1 (de) Verfahren und testsatz zur evaluierung der metastasierungstendenz von tumoren
DE59502359D1 (de) Verfahren zur festlegung des gültigkeitsbereichs für ein künstliches neuronales netzwerk
DK9600313U1 (da) Transportwire til rørskrabetransportører med beklædning omkring wiren og fremgangsmåde til fremstilling af denne.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1493439

Country of ref document: EP